Defining Success in Multiple Myeloma Induction and Maintenance

Opinion
Video

Three physicians explore the criteria for determining an adequate or successful response during the induction phase in patients with TE NDMM and uncover the intricate considerations shaping the choice of maintenance regimens.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.
Barry Paul, MD, listed cilta-cel, anito-cel, and arlo-cel as 3 of the CAR T-cell therapies with the most promising efficacy in patients with multiple myeloma.
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.